** Shares of Akebia Therapeutics AKBA.O down 26.1% at $2.10 before the bell after co raises equity at steep discount
** Cambridge, Massachusetts-based co focused on kidney disease late Weds announced pricing of 25 mln shares at $2 for $50 mln gross proceeds
** Offering priced at 29.6% discount to last sale
** AKBA shares rose ~11% on Weds, capping a four-session winning streak in which they racked up a 68% gain
** On Mar 13, co reported Q4 results and said it expects its anemia drug, branded as Vafseo, to generate $10-$11 mln of net product revs in Q1
** Co to use net offering proceeds to fund working capital and general corporate purposes, including R&D and commercial activities for its products and pipeline candidates, per the SEC prospectus filing
** With ~236.2 mln shares outstanding, per the latest 10-K filing, AKBA has ~$670 mln market cap
** Leerink Partners and Piper Sandler are jt bookrunners for the stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。